At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 65 enrolled
Drug / intervention
Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/II, Randomized, Blinded and Placebo-controlled Trial to Evaluate the Safety and Potential Efficacy of Allogeneic Human Mesenchymal Stem Cell Infusion in Patients With Aging Frailty
In Brief
A Phase 2 clinical trial evaluating Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs), Placebo, and 1 other intervention for Frailty. Completed, enrolled 65 participants across 1 site.
Detailed Summary
The purpose of this study is to look at the safety of treatment with stem cells in patients with Frailty.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFrailty
CountriesUnited States
CollaboratorsThe Emmes Company, LLC
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedFeb 2014
Enrollment StartMar 2014
Primary CompletionOct 2019
Study CompletionOct 2020
TodayJul 2026
First PostedFeb 17, 2014
Enrollment StartMar 3, 2014
Primary CompletionOct 2, 2019
Study CompletionOct 2, 2020
TodayJul 2, 2026
Enrollment to primary: 5.6 yearsPosted 12.4 years ago
Interventions
Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)biological
Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) administered by peripheral intravenous infusion
Placebobiological
Placebo administered by peripheral intravenous infusion.
Penicillin/Streptomycin-Free Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)biological
Penicillin/Streptomycin-Free Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) administered by peripheral intravenous infusion.